In support of the importance of CCL5 and its receptors for BBB regulation, animal studies of epilepsy demonstrated that antagonist-based inhibition of CCR5 on blood cells or blocking CCL5 can reduce BBB permeability and mitigate disease severity (35). Here, CCR5 is linked to epilepsy.